Savient Pharmaceuticals, Inc. Bankruptcy New Filing Alert: Motion For An Extension Of A Pending Deadline

On February 12, 2015, a motion for an extension of a pending deadline was filed in the bankruptcy case of Savient Pharmaceuticals, Inc. and its affiliates.

The filing was assigned docket number 839 and is described on the court’s official docket as follows:

Third Motion to Extend for Order Pursuant to Bankruptcy Case Section 105(a) and Bankruptcy Rule 9006(b) Extending Time Period Within Which Liquidating Trustee May Remove Actions Pursuant to 28 U.S.C. § 1452 and Bankruptcy Rule 9027 Filed by SPI Liquidating Trust. Hearing scheduled for 3/17/2015 at 11:30 AM at US Bankruptcy Court, 824 Market St., 5th Fl., Courtroom #4, Wilmington, Delaware. Objections due by 2/26/2015. (Attachments: # (1) Notice # (2) Exhibit A # (3) Certificate of Service and Service List) (Keane, Peter J.)

Savient Pharmaceuticals, Inc. filed for bankruptcy protection, or had an involuntary bankruptcy petition filed against it, on October 14, 2013. The bankruptcy case is pending before the United States Bankruptcy Court for the District of Delaware. The case number for the lead bankruptcy case is 13-12680. The bankruptcy case is currently assigned to United States Bankruptcy Judge Mary Walrath. The law firm of Skadden, Arps, Slate, Meagher & Flom LLP is acting as lead bankruptcy counsel to Savient Pharmaceuticals, Inc. in the bankruptcy case.


Leave a Reply